What is resistance to vankomycin?

Excessive use of antibiotics has created mutated forms of disease causing bacteria, often referred to as "Superbugs". The ability of vancomycin first published in 1958 to treat an infection threatening life because bacteria adapted to the threat of this antibiotics. Vankomycin resistance in superbugs spreads the ability of the body to mutate and share genetic material from other resistant bacterial strains. Some bacteria have become so resistant that no antibiotic is left to treat the resulting infection. The war against s. Aureus was initially won with the development of antibiotics; However, some tribes of these bacteria have developed resistance to the most effective drug, meticillin. As Meticillin Resistant s. In the United States, MRSA was responsible for more deaths in 2005 than AIDS. MRSA was also responsible for more serious infections than bacteriaPneumonia, flu or bacterial meningitis.

older, less frequently used antibiotics has become a new defense line against superbugs like MRSA. While most antibiotics inhibit bacterial enzymes, vancomycin works inhibition of cell wall synthesis so that bacteria bursts and dies. It was assumed that bacteria would be less likely to develop resistance to vancomycin due to this way. Vankomycin was not only effective against s.

Increasing popularity of vancomycin F or Superbuga treatment has become its fall. In 1986, Vankomycin resistance was identified in enterococcal abdominal infections. This resistance was caused by a gene called a bathtub that unfortunately was picked up s. Aureus n s. Aureus (Vrsa). The first VRSA was reported in the United States in 2002. Other ways of resistance to vancomycin are continued to be identified, which increases concerns that these superbugs could start spreading rapidly.

Risk factors for developing infection resistant to vankomycin include previous MRSA infections and previous vancomycin exposure. Most vancomycin -resistant infections occur in patients who have recently undergone major surgery or who have serious diseases such as cancer, diabetes or kidney failure. Some studies suggest that initial low doses of vancomycin at the beginning of treatment may be associated with resistant bacteria.